Skip to main
MYO

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc. has demonstrated a consistent increase in its reimbursement pipeline, growing from 1,389 units in Q4 to 1,669 units in Q3, indicating a strong demand for its myoelectric orthosis products. The company is strategically redirecting its growth towards the large Medicare market, which is projected to contribute approximately 22% of revenue in 2024, enhancing its revenue potential. Additionally, the recent positive ruling from CMS to include MyoPro under Medicare Part B benefits significantly expands Myomo's market reach and potential for revenue growth.

Bears say

Myomo Inc has revised its 2025 revenue guidance downward, projecting a range of $40 to $42 million, significantly reduced from the previous estimate of $50 to $53 million, indicating potential difficulties in reaching its financial targets. The company has also experienced a decline in its authorized insurance backlog, dropping from 272 at the end of Q4 to 208 in the most recent period, which suggests diminishing demand or issues with sales execution. Additionally, challenges in marketing and pipeline quality have negatively impacted lead generation and conversion rates, further contributing to concerns about the company's future financial performance.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.